100 CAMPUS DRIVE, FLORHAM PARK, NJ
Market cap: $10.7M (2/09/2026)
Price: $3.34
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Earnings Release
Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refract
Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Other Events
News, Articles of Incorporation
Announces One-for-Thirty Reverse Stock Split
Shareholder votes
Q3
Q2
Q1
FY 2024
Notice of Late Filing for Quarterly Report
Amended Quarterly Report
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report